Comparative Pharmacology
Head-to-head clinical analysis: PARICALCITOL versus VECTICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARICALCITOL versus VECTICAL.
PARICALCITOL vs VECTICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
VECTICAL (calcitriol) is a vitamin D analog that binds to vitamin D receptors (VDRs) in target tissues, increasing intestinal calcium absorption, renal calcium reabsorption, and enhancing osteoclast activity to mobilize calcium from bone, thereby raising serum calcium levels.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
1-2 mcg orally twice daily, increased every 2-4 weeks based on serum calcium and PTH levels. Maximum dose: 4 mcg twice daily.
None Documented
None Documented
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateParicalcitol + Methyclothiazide
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Mean terminal elimination half-life is approximately 3.7 hours (range 2.5–5.5 hours) in healthy adults. Clinically, steady-state is achieved within 2–3 days.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Primarily hepatobiliary (74%) and fecal (14%), with renal excretion accounting for <1% of the administered dose as unchanged drug. Enterohepatic recirculation occurs.
Category C
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Methyclothiazide."